Clinical trials: Refractory Ulcerative Colitis
Ulcerative Colitis
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.
- Trial name
- NCT00307827
- Testing
- Visilizumab
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Abbott
Ulcerative Colitis
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
- Trial name
- NCT00279422
- Testing
- visilizumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 127 people
- Sponsor
- Facet Biotech
Ulcerative Colitis, Active Moderate
Adacolumn in Refractory UC Patients Trial
The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients.
- Trial name
- ART (NCT01481142)
- Testing
- (GMA) Adsorptive Apheresis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Ulcerative Colitis
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.
- Trial name
- NCT00279435
- Testing
- visilizumab
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 25 people
- Sponsor
- Facet Biotech
Ulcerative Colitis
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
The purpose of this study is to compare two different dosing regimens of phosphatidylcholine versus placebo for the induction of remission in ulcerative colitis patients non-responsive to standard mesalamine treatment.
- Trial name
- PROTECT-1 (NCT02142725)
- Testing
- LT-02
- Where
- Germany
- Volunteers
- 468 people
- Sponsor
- Dr. Falk Pharma GmbH
Ulcerative Colitis
Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients
This study is designed as a proof of concept of KRP203 for induction of remission in ulcerative colitis (UC). The purpose of this study is to evaluate clinical benefit of KRP203 in subjects with moderately active refractory…
- Trial name
- NCT01375179
- Testing
- KRP203
- Where
- 14 sites in Belgium, Germany and 4 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active…
- Trial name
- NCT03093259
- Testing
- ABX464
- Where
- 19 sites in Austria, Belgium and 6 more
- Volunteers
- 32 people
- Sponsor
- Abivax S.A.
UC
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
A Single-Center, Open-Label, Single-Arm Exploratory Clinical Study on the Use of Autologous CAR-T Cell Therapy Injection for the Treatment of Refractory and Relapsing Ulcerative Colitis: A Preliminary Exploration of 12-Week…
- Trial name
- NCT07435779
- Testing
- BCMA CAR-T or CD19 CAR-T or CD19×BCMA
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.